A novel rapid test for detecting antibody responses to Loa loa infections.

Ivermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in...

Full description

Bibliographic Details
Main Authors: Bijan Pedram, Valérie Pasquetto, Papa M Drame, Yongchang Ji, Maria J Gonzalez-Moa, Richard K Baldwin, Thomas B Nutman, Marco A Biamonte
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-07-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC5531435?pdf=render
id doaj-75e896981e0d41149101d542497e8617
record_format Article
spelling doaj-75e896981e0d41149101d542497e86172020-11-25T01:32:48ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-07-01117e000574110.1371/journal.pntd.0005741A novel rapid test for detecting antibody responses to Loa loa infections.Bijan PedramValérie PasquettoPapa M DrameYongchang JiMaria J Gonzalez-MoaRichard K BaldwinThomas B NutmanMarco A BiamonteIvermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in a subset of individuals with high circulating levels of Loa loa microfilariae. Extending MDA to areas with coincident L. loa infection is problematic, and inexpensive point-of-care tests for L. loa are acutely needed. Herein, we present a lateral flow assay (LFA) to identify subjects with a serological response to Ll-SXP-1, a specific and validated marker of L. loa. The test was evaluated on serum samples from patients infected with L. loa (n = 109) and other helminths (n = 204), as well as on uninfected controls (n = 77). When read with the naked eye, the test was 94% sensitive for L. loa infection and was 100% specific when sera from healthy endemic and non-endemic controls or from those with S. stercoralis infections were used as the comparators. When sera of patients with O. volvulus, W. bancrofti, or M. perstans were used as the comparators, the specificity of the LFA was 82%, 87%, and 88%, respectively. A companion smartphone reader allowed measurement of the test line intensities and establishment of cutoff values. With a cutoff of 600 Units, the assay sensitivity decreased to 71%, but the specificity increased to 96% for O. volvulus, 100% for W. bancrofti, and 100% for M. perstans-infected individuals. The LFA may find applications in refining the current maps of L. loa prevalence, which are needed to eliminate onchocerciasis and lymphatic filariasis from the African continent.http://europepmc.org/articles/PMC5531435?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Bijan Pedram
Valérie Pasquetto
Papa M Drame
Yongchang Ji
Maria J Gonzalez-Moa
Richard K Baldwin
Thomas B Nutman
Marco A Biamonte
spellingShingle Bijan Pedram
Valérie Pasquetto
Papa M Drame
Yongchang Ji
Maria J Gonzalez-Moa
Richard K Baldwin
Thomas B Nutman
Marco A Biamonte
A novel rapid test for detecting antibody responses to Loa loa infections.
PLoS Neglected Tropical Diseases
author_facet Bijan Pedram
Valérie Pasquetto
Papa M Drame
Yongchang Ji
Maria J Gonzalez-Moa
Richard K Baldwin
Thomas B Nutman
Marco A Biamonte
author_sort Bijan Pedram
title A novel rapid test for detecting antibody responses to Loa loa infections.
title_short A novel rapid test for detecting antibody responses to Loa loa infections.
title_full A novel rapid test for detecting antibody responses to Loa loa infections.
title_fullStr A novel rapid test for detecting antibody responses to Loa loa infections.
title_full_unstemmed A novel rapid test for detecting antibody responses to Loa loa infections.
title_sort novel rapid test for detecting antibody responses to loa loa infections.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2017-07-01
description Ivermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in a subset of individuals with high circulating levels of Loa loa microfilariae. Extending MDA to areas with coincident L. loa infection is problematic, and inexpensive point-of-care tests for L. loa are acutely needed. Herein, we present a lateral flow assay (LFA) to identify subjects with a serological response to Ll-SXP-1, a specific and validated marker of L. loa. The test was evaluated on serum samples from patients infected with L. loa (n = 109) and other helminths (n = 204), as well as on uninfected controls (n = 77). When read with the naked eye, the test was 94% sensitive for L. loa infection and was 100% specific when sera from healthy endemic and non-endemic controls or from those with S. stercoralis infections were used as the comparators. When sera of patients with O. volvulus, W. bancrofti, or M. perstans were used as the comparators, the specificity of the LFA was 82%, 87%, and 88%, respectively. A companion smartphone reader allowed measurement of the test line intensities and establishment of cutoff values. With a cutoff of 600 Units, the assay sensitivity decreased to 71%, but the specificity increased to 96% for O. volvulus, 100% for W. bancrofti, and 100% for M. perstans-infected individuals. The LFA may find applications in refining the current maps of L. loa prevalence, which are needed to eliminate onchocerciasis and lymphatic filariasis from the African continent.
url http://europepmc.org/articles/PMC5531435?pdf=render
work_keys_str_mv AT bijanpedram anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT valeriepasquetto anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT papamdrame anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT yongchangji anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT mariajgonzalezmoa anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT richardkbaldwin anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT thomasbnutman anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT marcoabiamonte anovelrapidtestfordetectingantibodyresponsestoloaloainfections
AT bijanpedram novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT valeriepasquetto novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT papamdrame novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT yongchangji novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT mariajgonzalezmoa novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT richardkbaldwin novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT thomasbnutman novelrapidtestfordetectingantibodyresponsestoloaloainfections
AT marcoabiamonte novelrapidtestfordetectingantibodyresponsestoloaloainfections
_version_ 1725079758519140352